Supplemental material
Journal of Medical Economics
Volume 23, 2020 - Issue 11
Oncology
Cost utility analysis of tisagenlecleucel vs salvage chemotherapy in the treatment of relapsed/refractory diffuse large B-cell lymphoma from Singapore’s healthcare system perspective
Boon Piang Chera Agency for Care Effectiveness, Ministry of Health, Singapore, Singapore
https://orcid.org/0000-0001-5745-8133
https://orcid.org/0000-0001-5745-8133, Kar Yee Gana Agency for Care Effectiveness, Ministry of Health, Singapore, Singaporehttps://orcid.org/0000-0002-2406-2025
https://orcid.org/0000-0002-2406-2025, Mohamed Ismail Abdul Aziza Agency for Care Effectiveness, Ministry of Health, Singapore, Singaporehttps://orcid.org/0000-0003-3606-7672
https://orcid.org/0000-0003-3606-7672, , William Ying Khee Hwangb National Cancer Centre Singapore, Singapore, Singapore;c Department of Haematology, Singapore General Hospital, Singapore, Singapore;d Duke-NUS Medical School, Singapore, Singaporehttps://orcid.org/0000-0003-0143-6263
https://orcid.org/0000-0003-0143-6263, Li Mei Poone Department of Haematology-Oncology, National University Hospital Singapore, Singapore, Singaporehttps://orcid.org/0000-0002-8854-9414
https://orcid.org/0000-0002-8854-9414 & show all